6-Methyl-17α-pentyloxy-4,6-pregnadien-3,20-dione | 243638-34-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 6-Methyl-17α-pentyloxy-4,6-pregnadien-3,20-dione
• 英文别名: (8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-17-pentoxy-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 243638-34-8
• 化学式: C₂₇H₄₀O₃
• 分子量: 412.613
• InChiKey: CTEUHVNRWBYQIM-LOJVIFKASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-碘戊烷 、 甲地孕酮 在 氢氧化钾 作用下， 以 水 、 二甲基亚砜 为溶剂， 以7%的产率得到6-Methyl-17α-pentyloxy-4,6-pregnadien-3,20-dione
  参考文献：
  名称：

  Inhibitors of type 5 and type 3 17&bgr;-hydroxysteroid dehydrogenase and methods for their use

  摘要：

  揭示了针对对雄激素或雌激素活性敏感的疾病的医疗治疗和/或抑制疾病发展的新方法。这些治疗方法利用了5型和/或3型17β-羟基类固醇脱氢酶的抑制剂。还披露了新型的5型17β-羟基类固醇脱氢酶抑制剂，以及新型的3型17β-羟基类固醇脱氢酶抑制剂。

  公开号：

  US06541463B1

文献信息

• Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use
  申请人：Endorecherche, Inc.

  公开号：US20040082556A1

  公开（公告）日：2004-04-29

  Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17&bgr;-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17&bgr;-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17&bgr;-hydroxysteroid dehydrogenase.

  本发明揭示了一种针对对雄激素或雌激素活性敏感的疾病的新型医疗治疗和/或抑制疾病发展的方法。这些治疗方法利用了类型5和/或类型3的17β-羟基类固醇脱氢酶的抑制剂。本发明还揭示了新型的类型5 17β-羟基类固醇脱氢酶抑制剂，以及新型的类型3 17β-羟基类固醇脱氢酶抑制剂。
• Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
  申请人：Endorecherche Inc.

  公开号：EP1321146A2

  公开（公告）日：2003-06-25

  Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17β-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17β-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17β-hydroxysteroid dehydrogenase.

  针对对雄激素或雌激素活性敏感的疾病，公开了新的医疗和/或抑制疾病发展的方法。这些治疗方法利用了 5 型和/或 3 型 17β- 羟类固醇脱氢酶的抑制剂。还公开了 5 型 17β- 羟类固醇脱氢酶的新型抑制剂，以及 3 型 17β- 羟类固醇脱氢酶的新型抑制剂。
• Flocculated suspension of megestrol acetate
  申请人：Pharmaceutical Resources Inc.

  公开号：US20010048931A1

  公开（公告）日：2001-12-06

  A novel oral pharmaceutical composition in the form of a stable flocculated suspension in water is described as comprising: megestrol acetate; at least one compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerol, and sorbitol; and a surfactant, wherein polysorbate and polyethylene glycol are not simultaneously present.

  一种新型口服药物组合物以稳定的絮凝悬浮液形式存在于水中，其中包括：醋酸甲孕酮；至少一种选自由聚乙二醇、丙二醇、甘油和山梨醇组成的组的化合物；以及一种表面活性剂，其中聚山梨醇酯和聚乙二醇不同时存在。
• PHARMACEUTICAL SUSPENSIONS, COMPOSITIONS AND METHODS
  申请人：——

  公开号：US20020146455A1

  公开（公告）日：2002-10-10

  Abstract of Disclosure An aqueous pharmaceutical composition suitable for oral delivery has an insoluble active substance and a wetting agent in liquid suspension. The composition contains floccules of the active ingredient. The formulation has an excellent shelf-life in which caking and sedimentation are inhibited. The composition may be resuspended upon light to moderate shaking.

  公开内容摘要 一种适用于口服给药的水性药物组合物具有不溶性活性物质和润湿剂的液态悬浮液。 该组合物含有活性成分的絮状物。 该制剂具有极佳的保质期，可抑制结块和沉淀。 在轻度至中度振荡下，该组合物可重新悬浮。
• Flocculated pharmaceutical suspensions and methods for actives
  申请人：——

  公开号：US20030198679A1

  公开（公告）日：2003-10-23

  An aqueous pharmaceutical composition suitable for oral delivery has an insoluble active substance and one or more wetting agents in liquid suspension. The composition contains floccules of the active ingredient and is substantially free of polyethelyne glycol, propylene glycol, glycerol and sorbitol. The formulation has an excellent shelf-life in which caking and sedimentation are inhibited. The composition may be resuspended upon light to moderate shaking.

  一种适用于口服给药的水性药物组合物含有不溶性活性物质和一种或多种液态悬浮润湿剂。该组合物含有活性成分的絮状物，基本上不含聚乙二醇、丙二醇、甘油和山梨醇。该配方具有出色的保质期，可抑制结块和沉淀。轻微至适度摇晃即可重新悬浮。